Company intelligence / Profile preview

HAV

Newport Pagnell, England, United Kingdom

Ownership: Private
Employees: ~5
Development stage: Other

Overview

HAV Vaccines is a private UK biotechnology company developing therapeutic vaccines targeting chronic infections associated with inflammatory disease in humans and animals. The company is best known for its Mycobacterium avium subspecies paratuberculosis (MAP)-directed vaccine programs for Crohn's disease and Johne's disease. Its lead clinical work has involved heterologous viral-vectored vaccine candidates, including ChAdOx2-HAV and MVA-HAV, evaluated in a Phase 1b study in patients with active Crohn's disease. HAV Vaccines appears to operate as a small, specialist vaccine developer rather than a broad platform biopharma company.

Therapeutic areas: Infectious DiseasesGastroenterology
Modalities: VaccineT cell therapy
Industry: Biotech

Partnerships

University of OxfordKing's College London

Beyond the preview

Go deeper on HAV.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HAV.

Explore the full profile